EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
Nasdaq27d
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...
Yahoo Finance9d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
The Motley Fool4mon
Biogen Exceeds EPS Estimate, Revenue Declines
However, total revenue for the quarter slipped to $2.47 billion, a 3% decrease from the previous year's $2.53 billion, aligning with Biogen's guidance of a low-single digit percentage revenue ...